Advice
following a full submission:
umeclidinium (Incruse®) is accepted for use within NHS Scotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Two randomised controlled, phase III studies demonstrated that after 12 and 24 weeks of treatment umeclidinium improved lung function compared with placebo in patients with moderate to severe COPD. There was also improvement in symptomatic outcomes such as dyspnoea.
Umeclidinium is an alternative to other long-acting muscarinic antagonists (LAMAs).
Download detailed advice243KB (PDF)
Medicine details
- Medicine name:
- umeclidinium (Incruse)
- SMC ID:
- 1004/14
- Indication:
- as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2014